Camden National Corporation’s AbbVie ABBV Stock Holding History

Camden National Corporation’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$1.24M	Buy	+11,466	New	+$1.23M	0.25%	67

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Camden National Corporation's ABBV Position: Q1 2021 in Review

Camden National Corporation opened a new position in AbbVie (ABBV) in Q1 2021: 11,466 shares worth $1.24M. The stake represents 0.25% of the portfolio and ranks #67 among its holdings.

2,614 funds tracked by Wall St. Rank hold ABBV as of Q1 2021.

Camden National Corporation held 11,466 shares of AbbVie worth $1.24M as of Q1 2021.
AbbVie was a new Camden National Corporation position in Q1 2021.
AbbVie made up 0.25% of Camden National Corporation's portfolio in Q1 2021, its #67 holding.
2,614 funds tracked by Wall St. Rank held AbbVie as of Q1 2021.

Based on Camden National Corporation's 13F filing for Q1 2021, filed 12 May 2021.